Please provide your email address to receive an email when new articles are posted on . Higher fecal hemoglobin concentrations at baseline suggest a shorter repeat screening interval. Screening ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new national ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of the second annual “Closing the Gap: CRC Screening Insights” ...

The rise in CRC in adults younger than 65 underscores the need for early screening and prevention efforts. The report’s ...

Please provide your email address to receive an email when new articles are posted on . Annual fecal immunochemical testing was the most effective and cheapest CRC screening method for underserved ...

"Stool-based test offers a promising solution to reduce the burden of a colonoscopy," experts emphasized on September 21st, during the ICG 19 · Metagenomics for Health (ICG19·MH) & The 2nd MOHA ...

Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...

Over a 20-year period, colorectal cancer screening rates approximately doubled and mortality declined across all racial groups following systematic outreach. Colorectal cancer (CRC) screening rates ...

Guardant Health (NASDAQ:GH) executives used a Barclays discussion to outline growth drivers across treatment selection, minimal residual disease (MRD) testing, and colorectal cancer (CRC) screening, ...

Nearly half of new colorectal cancer cases now occur in people younger than age 65 years, highlighting the need for earlier ...